Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Waiser, J.
Right arrow Articles by Neumayer, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waiser, J.
Right arrow Articles by Neumayer, H.-H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1310-1317
© 2002 European Renal Association-European Dialysis and Transplant Association

Impact of the variability of cyclosporin A trough levels on long-term renal allograft function

Johannes Waiser1,, Torsten Slowinski1, Andrea Brinker-Paschke2, Klemens Budde1, Matthias Schreiber2, Torsten Böhler1, Ingeborg Hauser3 and Hans-Hellmut Neumayer1

1 Department of Internal Medicine-Nephrology, University Hospital Charité, Campus Charité Mitte, Humboldt-University, Berlin, 2 4th Medical Clinic, University of Erlangen-Nürnberg, Nürnberg and 3 Medical Clinic IV, University Frankfurt/Main, Frankfurt am Main, Germany

Background. Among renal allograft recipients, there is a considerable variability in cyclosporin A (CsA) trough levels. Some of the CsA metabolites are pharmacologically active. The variability of polyclonal CsA trough levels may contribute to the fact that long-term renal allograft survival is still not satisfactory. In a retrospective, single-centre study, we investigated the influence of the variability of polyclonal CsA trough levels on long-term renal allograft function.

Methods. Patients (n=381) received double immunosuppression consisting of CsA and methylprednisolone (MP). For each patient the CsA coefficient of variation (CCV) and the mean CsA trough level during the observation period (5 years) were calculated. Based on receiver operating characteristic (ROC) analysis, patients were divided into two groups: group I, CCV <28.05%, n=231; group II, CCV >28.05%, n=150. Additionally, patients were divided into three groups according to their mean CsA trough level: group A, <270 ng/ml, n=50; group B, 270–370 ng/ml, n=282; group C: >370 ng/ml, n=49.

Results. Compared to group I, patients in group II experienced a higher incidence of acute rejection episodes (40.7% vs 29.4%, P=0.02), reduced 5-year graft survival (81.1% vs 93.3%, P=0.002), and higher serum creatinine levels (1.7±1.2 mg/dl vs 1.4±0.5 mg/dl, P=0.03). In patients with low mean CsA trough levels, the incidence of acute rejection episodes was elevated (group A vs B, 50.0% vs 30.9%, P=0.008) and 5-year graft survival was reduced (group A vs B, 79.8% vs 89.5%, P=0.005). Multiple logistic regression analysis confirmed that the risk of graft failure within 5 years after transplantation was markedly elevated in group II (RR: 6.2, P=0.013) and in group A (RR: 8.9, P=0.008). Whereas the effect of CCV on 5-year graft survival was still evident in patients with normal or high mean CsA trough levels (>270 ng/ml, 81.9% vs 94.8%, P=0.0005), graft survival was independent from CCV in patients with low mean CsA trough levels (<270 ng/ml, 77.0% vs 81.7%, P=NS).

Conclusions. Both, the intra-individual variability and the mean of polyclonal CsA trough levels influence long-term renal allograft survival. Targeting at sufficiently high mean CsA levels with a low intra-individual variability may help to further improve long-term renal allograft survival.

Keywords: CsA trough level; cyclosporin A; graft function; kidney transplantation; single-centre study; variability

Correspondence and offprint requests to: Dr med. Johannes Waiser, Medizinische Klinik mit Schwerpunkt Nephrologie, Universitätsklinikum Charité, Campus Charité Mitte, Schumannstraße 20/21, D-10117 Berlin, Germany. Email: johannes.waiser{at}charite.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CJASNHome page
M. Naesens, D. R. J. Kuypers, and M. Sarwal
Calcineurin Inhibitor Nephrotoxicity
Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 481 - 508.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Buchler, S. Chadban, E. Cole, K. Midtvedt, E. Thervet, H. Prestele, and P. Keown
Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases
Nephrol. Dial. Transplant., January 1, 2006; 21(1): 197 - 202.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
D. Uehlinger, H.-P. Marti, M. Jadoul, and J.-P. Wauters
Sevelamer and pharmacokinetics of cyclosporin A after kidney transplantation
Nephrol. Dial. Transplant., March 1, 2005; 20(3): 661 - 661.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Einecke, I. Mai, L. Fritsche, T. Slowinski, J. Waiser, H.-H. Neumayer, and K. Budde
The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression
Nephrol. Dial. Transplant., January 1, 2004; 19(1): 215 - 222.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.